David Siegel, MD
Enriched profileChief, Myeloma Division, John Theurer Cancer Center; Founding Director, Institute for Multiple Myeloma · John Theurer Cancer Center
David Siegel is Chief, Myeloma Division, John Theurer Cancer Center; Founding Director, Institute for Multiple Myeloma at John Theurer Cancer Center. OpenAlex indexes 699 publications with 39,798 citations (h-index 83); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
David Siegel, MD, is Chief, Myeloma Division, John Theurer Cancer Center. The public record shows 699 publications with 39,798 citations (h-index 83), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma Research and Treatments
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 289.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Sponsor: Hackensack Meridian Health
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Sponsor: K36 Therapeutics, Inc.
Industry payments
Updated 15 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
- Janssen Biotech, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
63.1%Erythropoiesis-stimulating Agent61.3%Epoetin alfa100%Part B, office-administered≥16 patientsFactor Xa inhibitor1.8%Xarelto68%Eliquis33%Part D<11 patientsCancer & immunology
23.8%Thalidomide Analog20.9%Pomalyst59%Revlimid32%Lenalidomide9%Part D≥89 patientsKinase inhibitor2.1%Brukinsa100%Part D<11 patients+ 1 more class in this area
Anti-infectives
6.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5.1%Valacyclovir100%Part D≥49 patientsShort-acting sulfonamides1.2%Sulfamethoxazole-Trimethoprim100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
179 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 6651: Characterizing the risk of infections with T-cell engagers in multiple myeloma.
AACR Annual Meeting
AACR2026Co-author - Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.
Blood advances
Article2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
Blood cancer journal
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 02Antitumor Activity of Thalidomide in Refractory Multiple Myeloma2,591 citations1999
- 03Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2,449 citations2021
- 04
- 05Initial genome sequencing and analysis of multiple myeloma1,440 citations2011
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-siegel-md-25c3543a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/David-Siegel-15
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - X / Twitter
x.com/DavidSSiegelMD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/JTCancerCenter/posts/dr-david-siegel-chief-of-multiple-myeloma-at-john-theurer-cancer-center-at-hacke/10154683407070583
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - LinkedIn
linkedin.com/posts/john-theurer-cancer-center_dr-david-siegel-is-the-chief-of-the-myeloma-activity-6928343133785100288-rARR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD, New York University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Internal medicine internship/residency
New York University/Bellevue Hospital Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Fellowship
Hematology/Medical Oncology, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗ - Board certified
Internal Medicine and Medical Oncology; board eligible, Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →regionalcancercare.org ↗
Editorial & leadership roles
journal and society appointments- Founding Director
Institute for Multiple Myeloma and Lymphoma (iMML), Hackensack Meridian Health Center for Discovery & Innovation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hmh-cdi.org ↗ - Member
Steering Committee, Multiple Myeloma Research Consortium (MMRC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗
Awards & honors
honors on the public record- George H. Cook Honors Scholar (1979)
provisional, low-confidence; could not independently corroborate beyond the single bio source
1979provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗
Secondary affiliations
appointments beyond the home institution- Clinical Professor of Medicine
New York University (NYU) Medical Center / NYU School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →managingmyeloma.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →regionalcancercare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Myeloma Crowd Radio podcast/video interview
John Theurer Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens